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Bladder tumours represent between 3 and 5 per cent of all neoplasms and between 35 and 50 
per cent of all oncourological diseases [2]. Relapses occur in 75 per cent of the cases and 
approximately one third of the recurrent tumours are of an advanced stage and higher grade [8]. 
In order to decrease the great number of relapses, intravesical chemotherapy has been widely 
used nowadays. Thiotepa, Mitomycin С and Farmorubicin are considered to be some of the most 
effective local chemotherapeutics. 
Non-specific immunotherapy introduced in 1976 by Morales et al. [9] is a principally new 
approach in the treatment and prophylaxis of superficial bladder cancer. 
The well-expressed antigenicity of the BCG vaccine proved many times experimentally and 
clinically, the great cellular surface associated with the small size of superficial bladder tumours, 
the possibility of close contact between BCG and the tumour and prolonged (2 h) action on 
Table 1 
BCG strains used in intravesical therapy. Weight and strength 
Strain Weight / ampule Colony-forming units 
(CFU) 
Tice (Organon) 













2 - 6 x 1 0 ? C F U 
6 x 1 0 8 C F U 
8 - 3 2 x 1 0 8 C F U 
10XFU 
8 - 2 6 x 1 0 6 C F U 
2 x 109 viable bacilli 
109 viable bacilli 
bladder mucosa - all these factors demonstrate some unexpected possibilities for immunotherapy 
of superficial bladder cancer and make it most favourable for such treatment than any other 
human tumours. 
A great experience with BCG immunotherapy was accomplished in the recent 10-15 years. 
Summarized data show that this therapy was successful in about 60-90 per cent of the cases [7]. 
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There are several types of BCG vaccine prepared from different BCG strains and it is not clear 
yet whether all these strains are equally effective [5] (table 1). 
BCG GALGEVAX, a product of the Research Institute for Infectious and Parasitic Diseases, 
Sofia, was used first in 1983. It has been applied to more than 200 bladder tumour patients till 
now [1]. In June, 1987, the vaccine was used for the first time in the Clinic of Urology, Department 
of Surgery, Higher Institute of Medicine, Varna. 
This paper presents the early results of the non-specific immunotherapy and 
immunoprophylaxis with BCG CALGEVAX. It is an attempt to study the side-effects and the 
complications of BCG CALGEVAX due to its intravesical way of administration, to compare its 
efficacy to that of some local chemotherapeutics (Mitomycin С and Thiotepa) and to TUR alone, 
and, finally, to define its role and place in the complex treatment of bladder tumours. 
MATERIAL AND METHODS 
A total of 21 patients with histologically proved superficial bladder cancer (of stages pTjs, pTa 
and pTi) were covered in the present study. Two of them had persistent recurrent superficial 
bladder tumours. BCG CALGEVAX was used as a non-specific immunotherapy in this group. 
The rest 19 patients had no visible tumour, negative cytology and biopsy specimens at the initial 
examination. BCG CALGEVAX was applied as a prophylaxis against relapses in these cases. 
Tab le 2 
Patients' characteristics 
Parameter BCG CALGEVAX 
prophylaxis treatment 








































Patients' characteristics is presented on table 2. Tumour categories (stage and grade) are 
summarized on table 3. . 
All patients were treated by BCG CALGEVAX, CALGEVAX is produced by a special 
technology on the basis of BCG-I - Moscow strain which is very closely related to the original 
Calmette-Guerin's strain (BCG-Paris). One mg of BCG CALGEVAX contains 2,67 - 8,0 x 106 
viable bacilli [4|. 
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Т а Ы е З V 
Tumour categories 
1 urn • • 
Parameter BCG CALGEVAX 
prophylaxis treatment 





































(n = 10) 
Thiotepa (TT) 
(n = 8) 
TUR alone (n = 20) 
6 ml (120 mg) fluid or 5 ampules dry, 
[375 mg) suspended in 50 ml saline 
\ x week / 6 weeks 
1 x month / 1 year 
5 ampules (375 mg) dry 
1 x week / till response 
1 x month / 1 year 
30 mg 1 week / 8 weeks 
1 month /1 year 
1 week / 4 weeks 
1 month /1 year 
60 mg 
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The initial course includes 6 weekly instillations of 6 ml fluid (120 mg) or 5 ampules dry (375 
mg) of BCG CALGEVAX, both suspensed in 50 ml saline. It was followed by monthly instillations 
of the same doses for 1 year. 
Patients were asked to retain the vaccine for 2 hours. 
Control studies were done on admission to the protocol, after the initial course and every 3 
months thereafter. They included: cystoscopy (with or without) cold-cup biopsy; cytology; roll 
blood and urine analysis; routine microbiological, echographic, X-ray and radiological 
examinations; immune status, including* leukocyte count, proteinogram, percentage of T a and 1\ 
cells and i.d. test for immune deficiency, using standard antigens (tuberculin, candidin, tetanic 
anatoxin and trichophytin). 
The follow-up period was between 16 and 24 months. 
The first BCG instillation was usually done 1 month after the operation after the first control 
cystoscopy. 
Three other patients' groups (given Mitomycin C, Thiotepa and TUR alone) were used as 
controls in order to compare vaccine efficacy. Patients' age, tumour stage and grade, number of 
previous relapses, etc., were similar to these of the former BCG group (table 2 and 3). Treatment 
schedules used in these groups are presented on table 4. 
Statistical analysis was earned out by using of Student-Fisher's test. 
RESULTS AND DISCUSSION 
Patients from control groups were either without any complaints during treatment, or the latter 
were insignificant and self-limited: bladder irritability in a few cases and just one incident of 
haematuria in a Mitomycin С-treated patient (table 5). 
However, complaints of BCG-treated patients were much more expressed. All of them had 
dysuria which was quite severe in 3 (143 per cent) of the cases. One of these three patients had 
to be hospitalized and treated with tuberculostatics. In most cases dysuria was mild and transitory 
- lasting not longer than 2-3 days. Other side-effects, such as haematuria, fever, etc., were also 
noted (table 5). 
T a b l e 5 
Side-effects and complications 
Side-effects Mitomycin С 
n = 10 
Thioteoa BCG CALGEVAX 








1 (10 %) 
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Т а Ы е б 
Prophylactic results 




























BCG versus TUR alone, p < 0,05 
BCG versus MMC, p >0,05 
BCG versus TT, p > 0,05. 
Fig. L Staining with hemataxylin-eosin. Magn. x 100 
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Fig. 2 Staining with hemataxylin-eosin. Magi, x 200 
We did not establish any dangerous complications of BCG therapy described in the literature, 
such as TBC dissemination, granulomatous hepatitis, microcystis, etc. [12]. 
In spite of these considerable side-effects and possible complications of the intracavitary BCG 
application, yet, the recurrence rate in this group was the lowest one - 4 relapses only (21,05 per 
cent) (table 6). There was a significant difference (p,05) when it was compared with tie group of 
TUR alone (55 per cent of recurrences). However, this difference was not significant when the 
rest two groups were concerned (BCG versus Thiotepa and BCG versus Mitomycin C) (p0,05). 
A total of 78,3 per cent of all relapses in these groups have appeared in the first 12 months after 
TUR administration. 
BCG CALGEVAX proved to be efficient as therapeutic agent, too. One patient with two 
recurrent bladder tumours (of 3-5 mm in size) was free of them after 7 consecutive weekly 
instillations of BCG CALGEVAX, i.e. there was a complete curative effect. The cold-cup 
biopsies taken from the same place showed just non-specific inflammatory alterations without 
any signs of anaplasia. 
The second female patient had multiple recurrent tumours (T1G2). There was just a partial 
effect after 6 weekly instillations: some of the smaller tumours disappeared while the bigger ones 
lost their papillas and got a fibrous coating. We applied TUR of these tumours not waiting for a 
complete healing effect mainly because this patient had no immune deficiency and previously 
applied non-specific immunotherapy with Levamisol had not given the expected result. The 
histological examination of the resected tumours was very demonstrative. There were obvious 
degenerative changes and tumour mass reduction. 
The examination of patients' immune status revealed a manifested immune deficiency prior to 
BCG immunotherapy in approximately 90 per cent of our cases. Cellular immunity was favourably 
influenced after vaccine application in 55 per cent of the cases. This fact suggests that BCG 
CALGEVAX possesses a systemic effect when applied locally which makes its simultaneous 
percutaneous administration useless, indeed. Therefore, we accepted Morales' modified 
schedule who does not use i.d. BCG applications as well [10]. 
BCG CALGEVAX induces an intensive inflammatory response which involves the superficial 
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mucosa and submucosa (Fig. 1). We fail to establish any specific morphological changes - giant 
cells, microorganisms, etc. Lymphocytes and plasrnocytes represent the prevailing cellular type 
(Fig. 2). We relate their local accumulation to the good therapeutic results. However, we could 
not prove their exact role in the intimate mechanisms of the immune response. 
The most important issue concerning BCG immunotherapy consists in the unclarified 
mechanisms of BCG antitumour activity. BCG may in dependence on the dose, manner of 
application and its timing, exert a stimulating or suppressive effect. It has the potential to act as 
a non-specific immunomodulator by various ways involving different cells of the immune system. 
Recently, in addition to these systemic effects, a great attention is paid to the local antitumour 
effect of the vaccine. 
Boehle et al. [3] report a considerable local Т-cell proliferation as a response to the BCG-
induced inflammation. The absolute number of mononuclear cells increases significantly after 
BCG therapy. Besides the ratio of local T-helper/T-suppressor cells is inverse showing a value of 
2:1. An intensive cytokine (IL-1,11^2, TNF) production is also established. The detection of B-
cells which are absent in the normal bladder in the early period after BCG instillation indicates 
the involvement of the humoral component of the immune response, too. The activation of 
peripheral macrophages after intravesical BCG is previously described 111]. The massive local 
infiltration with macrophages emphasizes their role as effector cells in the focal immune response. 
All these data demonstrate a complex local immune response to the BCG - induced inflammation 
involving the cellular and humoral components of the immune system. 
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ИММУНОТЕРАПИЯ РАКА МОЧЕВОГО ПУЗЫРЯ 
А. ХинеВ, Д. Гочев, А. ЭнгибароВ, В. АйладыноВ, Л. РаличкоВа, К. КисеВа, М. ЧучкоВа 
Р Е З Ю М Е 
21 пациенту со злокачественной опухолью мочевого пузыря интракавитарно была введена бацилла Кальмета-
Гсрсна (БЦЖ) в качестве нсспецифичной иммунотерапии и иммунопрофилактики. !>ЦЖ КАЛЬГЕВАКС (6 мл 
жидкой /120 мг/ или 5 ампул сухой /375 мг/ вакцины, растворенной в 50 мл физиологической сыворотки), вводилась 
в мочевой пузырь один раз н неделю в течение 6 недель как начальный курс лечения, вслед за которым делались 
месячные инстиляции до одною юла. Непосредственно перед лечением, после окончания начального курса и 
через каждые три месяца после нею проводились контрольные исследования: иммунный статус, цистоскопия с 
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биопсией при помощи щипц, цитологическое исследование мочи, рутинные лабораторные,эхо графские, 
рентгенологические и радиологические исследования. Период наблюдения был между 16 и 24 месяцами, в 
среднем - в течение 19 месяцев. 
Были отмечены наиболее частые побочные эффекты: раздражение мочевого пузыря (100 %), гематурия 
(42,9 %), повышенная температура (38,1 %) и другие. Большинство из них однако являлись легкими и длились не 
более двух-трех дней. 
Эффективность м « ч и н » была сопоставлена с эффективностью некоторых локальных химиотерапевтических 
средств (Митомицина С и Тиотепа), как и с самой ТУР. В качестве иммунопрофилактического средства БЦЖ 
КАЛЬГЕВАКС показала наиболее ниский процент рецидивов - 4 (21,05 %) , по сравнению с самой ТУР - 11 
(55 %) (р<0,05); с Митомицином С - 5 (50 %) и с Тиотепом - 3 (37,5 %). В качестве иммунотерапевтического 
средства БЦЖ КАЛЬГЕВАКС достигла полного ответа у одного пациента и частичного ответа у другого. 
Эти хорошие терапевтические результаты очевидно связаны с индуцированным вакциной БЦЖ локальным 
иммунным ответом, проявлением которого является накопление лимфоцитов и плазмоцитов в мукозном и 
субмукозном слоях мочевого пузыря. 
